Forward Pharma (Germany)
Forward Pharma A/S is a Danish biopharmaceutical company that from 2005 to 2017 developed a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.
Basic Information
- Category: business
- Website: https://forward-pharma.com/
Documented Facts
- Inception (Wikidata): 2005 (Source 2: Wikidata Q30268967, revision 2474177978)
- Country (Wikidata; date unspecified): Germany (Source 2: Wikidata Q30268967, revision 2474177978; Source 3: Wikidata label: Q183, revision 2557182420)
- Official website (Wikidata; date unspecified): https://forward-pharma.com/ (Source 2: Wikidata Q30268967, revision 2474177978)
Evidence and Sources
- Forward Pharma (Germany) — Official Website (official)
- Wikidata Q30268967, revision 2474177978 (knowledge-base)
- Wikidata label: Q183, revision 2557182420 (knowledge-base)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Forward Pharma (Germany).
- Canonical profile: https://brandsource.ai/brands/forward-pharma-germany
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/forward-pharma-germany/json-ld
- Citation profile API: https://brandsource.ai/api/brands/forward-pharma-germany/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Forward Pharma A/S is a Danish biopharmaceutical company that from 2005 to 2017 developed a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.